Key Points
- United Therapeutics CFO James Edgemond sold 10,000 shares on May 21 for about $5.64 million at an average price of $564.11. After the sale, he still held 18,876 shares, but his position was reduced by 34.63%.
- Edgemond has been actively trimming his stake throughout May and April, including multiple additional 10,000-share sales over the prior weeks. The repeated transactions suggest a sustained pattern of insider selling rather than a one-time trade.
- United Therapeutics shares opened at $568.43, near their 50-day average of $563.25 and close to their 52-week high of $609.35. The company recently reported earnings of $5.82 per share, missing analyst estimates, while Wall Street still largely rates the stock a Moderate Buy.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,648,140.36. This represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
James Edgemond also recently made the following trade(s):
- On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
- On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
- On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.
- On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00.
- On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total transaction of $5,769,300.00.
- On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00.
- On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total transaction of $5,688,300.00.
- On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
- On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56.
- On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
United Therapeutics Price Performance
Shares of UTHR stock opened at $568.43 on Friday. The company has a market capitalization of $24.13 billion, a price-to-earnings ratio of 20.98, a PEG ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company's fifty day moving average price is $563.25 and its 200-day moving average price is $511.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.63 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.
Institutional Trading of United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Arjuna Capital grew its stake in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after buying an additional 18 shares in the last quarter. Clearstead Advisors LLC boosted its stake in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after purchasing an additional 23 shares during the period. Sage Rhino Capital LLC boosted its stake in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC boosted its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after purchasing an additional 24 shares during the period. Finally, Meeder Advisory Services Inc. boosted its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 26 shares during the period. 94.08% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on UTHR shares. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Finally, Royal Bank Of Canada reduced their price target on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $619.42.
Read Our Latest Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
